Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumors

In brief

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of weekly dosing of CRLX101 (both as monotherapy; (Schedule 1) and in combination with bevacizumab every 2 weeks (Schedule 2) and weekly with a 3 week on / 1 week off schedule in combination with mFOLFOX6 (Schedule 3) to affirm the dose for future clinical studies.

Key facts

Study ID

NCT02648711

Run by

NewLink Genetics Corporation

People needed

41

Starts

2015-10-01

Expected to finish

2018-05-07

Last updated by the study team

2020-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• START Midwest/Cancer & Hematology Centers of Western Michigan, PC — Grand Rapids, Michigan, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• South Texas Accelerated Research Therapeutics (START), LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.